| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel
1 company
Devin Whittemore Smith last filed a Form 4 in April 2025, as General Counsel at IOBT. Devin Whittemore Smith's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 16,938 shares of IOBT. Net of sales, the IOBT filings show accumulation of 12,000 shares.
Devin Whittemore Smith has 10 Form 4 filings on record from August 2018 to April 2025, across 2 companies: General Counsel at IO Biotech (IOBT), 2023–2025; SVP and General Counsel at Minerva Neurosciences (NERV), 2018–2020.
The 11 reported transactions were 9 option or other derivative awards, 1 open-market purchase and 1 stock award.
Counted by filing, the open-market trades come to 1 purchase worth about $10K and no sales.
The only open-market purchase was 12,000 shares of IOBT at an average $0.81 on December 23, 2024, about $10K. Twelve months later IOBT was down 21%.
Shares as reported in the last Form 4 for each company; the most recent is from April 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 23, 2024 | IOBT Io Biotech, Inc. | General Counsel | Buy | 12,000 | $0.81 | $9,720.00 | +243.0% | +12.4% | -21.3% |